-$1.4 (-2.95%)
| Source | Headline |
|---|---|
|
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests
10,000 Common Stock shares were sold for a transaction value of $402,000 at an average price of around $40.24 per share on June 18, 2026. The sale represented 38% of Halpin's direct Common Stock holdings, reducing his direct stake from 26,248 to 16,248 shares, though he also has options. fool.com - 2026-06-27 12:58:26 |
|
Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16th, 2026. globenewswire.com - 2026-06-09 08:30:00 |
|
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States. fool.com - 2026-05-30 14:39:34 |
|
Vericel Q1 Earnings Call Highlights
Vericel NASDAQ: VCEL reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract. marketbeat.com - 2026-05-09 02:10:08 |
|
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-05-07 23:31:13 |
|
Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates
Vericel Corporation (VCEL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago. zacks.com - 2026-05-07 12:16:20 |
|
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91% globenewswire.com - 2026-05-07 07:45:00 |
|
Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 53.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 2026-05-04 10:56:10 |
|
Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026
CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2026 financial results on Thursday, May 7, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. globenewswire.com - 2026-04-23 08:30:00 |